2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

BD released findings from a survey conducted by The Harris Poll that indicate a significant gap in women’s knowledge about the primary causes of cervical cancer as well as the most effective means of prevention.
Cervical Cancer | News & Updates
Press Release: New Harris Poll Reveals Significant Gaps in Women's Knowledge About Cervical Cancer
A healthy and happy woman with a cellphone
Vaginitis | Brochures
BD Vaginal Panel Reimbursement and Market Access Toolkit
ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women
Cervical Cancer | News & Updates
ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women